Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 22

1.

RPC4046, a Monoclonal Antibody Against IL13, Reduces Histologic and Endoscopic Activity in Patients With Eosinophilic Esophagitis.

Hirano I, Collins MH, Assouline-Dayan Y, Evans L, Gupta S, Schoepfer AM, Straumann A, Safroneeva E, Grimm M, Smith H, Tompkins CA, Woo A, Peach R, Frohna P, Gujrathi S, Penenberg DN, Li C, Opiteck GJ, Olson A, Aranda R, Rothenberg ME, Dellon ES; HEROES Study Group.

Gastroenterology. 2019 Feb;156(3):592-603.e10. doi: 10.1053/j.gastro.2018.10.051. Epub 2018 Nov 2.

2.

Cardiac Safety of Ozanimod, a Novel Sphingosine-1-Phosphate Receptor Modulator: Results of a Thorough QT/QTc Study.

Tran JQ, Hartung JP, Olson AD, Mendzelevski B, Timony GA, Boehm MF, Peach RJ, Gujrathi S, Frohna PA.

Clin Pharmacol Drug Dev. 2018 Mar;7(3):263-276. doi: 10.1002/cpdd.383. Epub 2017 Aug 7.

3.

Results From the First-in-Human Study With Ozanimod, a Novel, Selective Sphingosine-1-Phosphate Receptor Modulator.

Tran JQ, Hartung JP, Peach RJ, Boehm MF, Rosen H, Smith H, Brooks JL, Timony GA, Olson AD, Gujrathi S, Frohna PA.

J Clin Pharmacol. 2017 Aug;57(8):988-996. doi: 10.1002/jcph.887. Epub 2017 Apr 11.

4.

Ozanimod Induction and Maintenance Treatment for Ulcerative Colitis.

Sandborn WJ, Feagan BG, Wolf DC, D'Haens G, Vermeire S, Hanauer SB, Ghosh S, Smith H, Cravets M, Frohna PA, Aranda R, Gujrathi S, Olson A; TOUCHSTONE Study Group.

N Engl J Med. 2016 May 5;374(18):1754-62. doi: 10.1056/NEJMoa1513248.

5.

Safety and efficacy of the selective sphingosine 1-phosphate receptor modulator ozanimod in relapsing multiple sclerosis (RADIANCE): a randomised, placebo-controlled, phase 2 trial.

Cohen JA, Arnold DL, Comi G, Bar-Or A, Gujrathi S, Hartung JP, Cravets M, Olson A, Frohna PA, Selmaj KW; RADIANCE Study Group.

Lancet Neurol. 2016 Apr;15(4):373-81. doi: 10.1016/S1474-4422(16)00018-1. Epub 2016 Feb 12.

PMID:
26879276
6.

Safety of abatacept administered intravenously in treatment of rheumatoid arthritis: integrated analyses of up to 8 years of treatment from the abatacept clinical trial program.

Weinblatt ME, Moreland LW, Westhovens R, Cohen RB, Kelly SM, Khan N, Pappu R, Delaet I, Luo A, Gujrathi S, Hochberg MC.

J Rheumatol. 2013 Jun;40(6):787-97. doi: 10.3899/jrheum.120906. Epub 2013 Apr 15.

7.

Anti-IP-10 antibody (BMS-936557) for ulcerative colitis: a phase II randomised study.

Mayer L, Sandborn WJ, Stepanov Y, Geboes K, Hardi R, Yellin M, Tao X, Xu LA, Salter-Cid L, Gujrathi S, Aranda R, Luo AY.

Gut. 2014 Mar;63(3):442-50. doi: 10.1136/gutjnl-2012-303424. Epub 2013 Mar 5.

8.

Association between single nucleotide polymorphism in collagen IX and intervertebral disc disease in the Indian population.

Rathod TN, Chandanwale AS, Gujrathi S, Patil V, Chavan SA, Shah MN.

Indian J Orthop. 2012 Jul;46(4):420-6. doi: 10.4103/0019-5413.97261.

9.

Abatacept for Crohn's disease and ulcerative colitis.

Sandborn WJ, Colombel JF, Sands BE, Rutgeerts P, Targan SR, Panaccione R, Bressler B, Geboes K, Schreiber S, Aranda R, Gujrathi S, Luo A, Peng Y, Salter-Cid L, Hanauer SB.

Gastroenterology. 2012 Jul;143(1):62-69.e4. doi: 10.1053/j.gastro.2012.04.010. Epub 2012 Apr 12.

PMID:
22504093
10.

Abatacept in subjects who switch from intravenous to subcutaneous therapy: results from the phase IIIb ATTUNE study.

Keystone EC, Kremer JM, Russell A, Box J, Abud-Mendoza C, Elizondo MG, Luo A, Aranda R, Delaet I, Swanink R, Gujrathi S, Luggen M.

Ann Rheum Dis. 2012 Jun;71(6):857-61. doi: 10.1136/annrheumdis-2011-200355. Epub 2012 Feb 2.

PMID:
22302417
11.

Evaluation of abatacept administered subcutaneously in adults with active rheumatoid arthritis: impact of withdrawal and reintroduction on immunogenicity, efficacy and safety (phase Iiib ALLOW study).

Kaine J, Gladstein G, Strusberg I, Robles M, Louw I, Gujrathi S, Pappu R, Delaet I, Pans M, Ludivico C.

Ann Rheum Dis. 2012 Jan;71(1):38-44. doi: 10.1136/annrheumdis-2011-200344. Epub 2011 Sep 13.

12.

Belatacept-based regimens are associated with improved cardiovascular and metabolic risk factors compared with cyclosporine in kidney transplant recipients (BENEFIT and BENEFIT-EXT studies).

Vanrenterghem Y, Bresnahan B, Campistol J, Durrbach A, Grinyó J, Neumayer HH, Lang P, Larsen CP, Mancilla-Urrea E, Pestana JM, Block A, Duan T, Glicklich A, Gujrathi S, Vincenti F.

Transplantation. 2011 May 15;91(9):976-83. doi: 10.1097/TP.0b013e31820c10eb.

PMID:
21372756
13.

An integrated safety profile analysis of belatacept in kidney transplant recipients.

Grinyó J, Charpentier B, Pestana JM, Vanrenterghem Y, Vincenti F, Reyes-Acevedo R, Apanovitch AM, Gujrathi S, Agarwal M, Thomas D, Larsen CP.

Transplantation. 2010 Dec 27;90(12):1521-7. doi: 10.1097/TP.0b013e3182007b95.

PMID:
21088650
14.

Five-year safety and efficacy of belatacept in renal transplantation.

Vincenti F, Blancho G, Durrbach A, Friend P, Grinyo J, Halloran PF, Klempnauer J, Lang P, Larsen CP, Mühlbacher F, Nashan B, Soulillou JP, Vanrenterghem Y, Wekerle T, Agarwal M, Gujrathi S, Shen J, Shi R, Townsend R, Charpentier B.

J Am Soc Nephrol. 2010 Sep;21(9):1587-96. doi: 10.1681/ASN.2009111109. Epub 2010 Jul 15.

15.

Targeting lymphocyte co-stimulation: from bench to bedside.

Felix NJ, Suri A, Salter-Cid L, Nadler SG, Gujrathi S, Corbo M, Aranda R.

Autoimmunity. 2010 Nov;43(7):514-25. doi: 10.3109/08916931003674741. Review.

PMID:
20429850
16.

Ocrelizumab, a humanized anti-CD20 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I/II randomized, blinded, placebo-controlled, dose-ranging study.

Genovese MC, Kaine JL, Lowenstein MB, Del Giudice J, Baldassare A, Schechtman J, Fudman E, Kohen M, Gujrathi S, Trapp RG, Sweiss NJ, Spaniolo G, Dummer W; ACTION Study Group.

Arthritis Rheum. 2008 Sep;58(9):2652-61. doi: 10.1002/art.23732.

17.

Endovascular repair of symptomatic renal transplant site pseudoaneurysm.

Moosavi CA, Gujrathi SK, Friedman A, Fox D, Silberzweig JE.

Vasc Endovascular Surg. 2008 Dec-2009 Jan;42(6):607-9. doi: 10.1177/1538574408320022. Epub 2008 Jul 11.

PMID:
18621888
18.

TENOR risk score predicts healthcare in adults with severe or difficult-to-treat asthma.

Miller MK, Lee JH, Blanc PD, Pasta DJ, Gujrathi S, Barron H, Wenzel SE, Weiss ST; TENOR Study Group.

Eur Respir J. 2006 Dec;28(6):1145-55. Epub 2006 Jul 26.

19.

Total serum IgE levels in a large cohort of patients with severe or difficult-to-treat asthma.

Borish L, Chipps B, Deniz Y, Gujrathi S, Zheng B, Dolan CM; TENOR Study Group.

Ann Allergy Asthma Immunol. 2005 Sep;95(3):247-53.

PMID:
16200815
20.

Filmless in New Jersey: the New Jersey Medical School PACS Project.

Hirschorn D, Eber C, Samuels P, Gujrathi S, Baker SR.

J Digit Imaging. 2002;15 Suppl 1:7-12. Epub 2002 Mar 20.

PMID:
12105690
21.

Intimate strangers.

Gujrathi S.

Pharos Alpha Omega Alpha Honor Med Soc. 1996 Winter;59(1):34-5. No abstract available.

PMID:
8819680
22.

Configurational statistics in a-SixNyHz alloys: A quantitative bonding analysis.

Bustarret E, Bensouda M, Habrard MC, Bruyère JC, Poulin S, Gujrathi SC.

Phys Rev B Condens Matter. 1988 Oct 15;38(12):8171-8184. No abstract available.

PMID:
9945569

Supplemental Content

Loading ...
Support Center